Morphic Holding, Inc. (MORF)
NASDAQ: MORF · IEX Real-Time Price · USD
28.66
-1.66 (-5.47%)
Apr 12, 2024, 4:00 PM EDT - Market closed

Company Description

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer.

Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease.

The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive.

In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications.

Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Morphic Holding, Inc.
Morphic Holding logo
Country United States
Founded 2014
IPO Date Jun 27, 2019
Industry Biotechnology
Sector Healthcare
Employees 121
CEO Dr. Praveen P. Tipirneni M.D.

Contact Details

Address:
35 Gatehouse Drive A2
Waltham, Massachusetts 02451
United States
Phone (781) 996-0955
Website morphictx.com

Stock Details

Ticker Symbol MORF
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001679363
CUSIP Number 61775R105
ISIN Number US61775R1059
Employer ID 47-3878772
SIC Code 2834

Key Executives

Name Position
Dr. Bruce N. Rogers Ph.D. President and Interim Principal Executive Officer
Dr. Timothy A. Springer Ph.D. Founder, Independent Director and Member of Scientific Advisory Board
Dr. Marc Schegerin M.B.A., M.D. Chief Financial Officer and Chief Operating Officer
Dr. Praveen P. Tipirneni M.D. Chief Executive Officer, MD and Director (Leave of Absence)
Robert E. Farrell Jr., CPA Senior Vice President of Finance and Chief Accounting Officer
Dr. Blaise Lippa Ph.D. Chief Scientific Officer
William D. DeVaul Esq. General Counsel and Secretary
Aaron Pelta Senior Vice President of Business and Corporate Development
Joanne Gibbons Senior Vice President of Regulatory Affairs
Dr. Simon Cooper MBBS Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 12, 2024 8-K Current Report
Feb 22, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 22, 2024 10-K Annual Report
Feb 22, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals